Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Debt / DBCV 0.250% 2/0
-
Number of holders
-
45
-
Total 13F principal, excl. options
-
487,265,640
-
Principal change
-
-545,825
-
Total reported value, excl. options
-
$485,318,710
-
Value change
-
-$192,336
-
Number of buys
-
13
-
Number of sells
-
-13
-
Price
-
$0.9950
Significant Holders of TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 as of Q4 2020
50 filings reported holding 88163VAE9 - TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 as of Q4 2020.
TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 has 45 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $487,265,640 of principal
.
Largest 10 bondholders include Radcliffe Capital Management, L.P. ($100,783,000 of principal), Arena Capital Advisors, LLC- CA ($68,443,000 of principal), WESTWOOD HOLDINGS GROUP INC ($43,125,000 of principal), JUPITER ASSET MANAGEMENT LTD ($35,000,000 of principal), Nuveen Asset Management, LLC ($29,276,000 of principal), WELLS FARGO & COMPANY/MN ($28,897,000 of principal), LMR Partners LLP ($22,235,000 of principal), ONTARIO TEACHERS PENSION PLAN BOARD ($17,400,000 of principal), INCOME RESEARCH & MANAGEMENT ($14,775,000 of principal), and VICTORY CAPITAL MANAGEMENT INC ($12,905,000 of principal).
This table shows the top 45 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.